In HCC, the upregulation of ligands (Wnt1, Wnt3A, etc.)and FZD receptors (FZD2 and FZD7), along with frequent CTNNB1 mutations, is linked to early tumorigenesis, elevated risk of recurrence, and worse clinical outcomes. This evidence concerns the gene FZD7 and hepatocellular carcinoma.